Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 33

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 
  
    Cash paid for operating lease liabilities 
    $31,882  
    $30,373  
    $95,645  
    $95,645 
  
    Cash paid for finance lease liabilities 
     3,417  
     2,685  
     10,251  
     8,055 
  
    Weighted Average Remaining Lease Term 

    Finance leases (years) 

      4.50 years   
      0.29
                                            years  
  
    Operating leases (years) 

     1.5
years   
      2.50 years  
  
    Weighted-average discount rate – operating leases 

     9.20% 
     9.20%
  
    Weighted-average discount rate – finance leases 

     9.20% 
     9.20%

NOTE
14— SUBSEQUENT EVENTS

On
November 7, 2025, Mr. Osser resigned from the Board of Directors. Mr. Osser will continue as Managing Director of China, and consultant
under his U.S. Asian agreement.

 19 

ITEM
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The
following discussions of the financial condition and results of operations should be read in conjunction with the financial statements
and the notes to those statements contained in this report and in connection with management’s discussion and analysis and the audited
consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024,
which was filed with the Securities and Exchange Commission, or SEC on April 15, 2025. Certain statements in this discussion and elsewhere
in this report constitute forward-looking statements, within the meaning of Section 21E of the Exchange Act, which involve risks and
uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.

OVERVIEW

Milestone Scientific is a biomedical technology company
that patents, designs, develops, and commercializes innovative diagnostic and therapeutic injection technologies for medical and dental
applications. Since our inception, we have pioneered proprietary computer-controlled injection systems that are proven, reliable, and
well established in clinical use. Our common stock has been listed on the NYSE American since June 1, 2015, under the symbol “MLSS.”
The Company’s mission is to redefine the global standard of